Results 241 to 250 of about 850,081 (293)

PARP inhibitors induce a senescence phenotype in non‐small cell lung carcinoma cell lines

FEBS Open Bio, EarlyView.
Talazoparib is the most potent inducer of senescence among different PARP1 inhibitors in human NSCLC cells. In the absence of PARP, no senescence phenotype was observed, demonstrating that PARP1 is necessary for the induction of senescence by this inhibitor.
Camille Huart, Manon Van den Abbeel, Christoph Schifflers, Karim Bouhjar, Andrea Scarmelotto, Alexis Khelfi, Anne‐Catherine Wera, Carine Michiels   +7 more
wiley   +1 more source

Caution required in interpreting inflammatory effects of e-cigarette use: correcting methodological and conceptual weaknesses

Respiratory Research
Lucia Spicuzza, Francesco Pennisi, Davide Campagna   +2 more
doaj   +1 more source

Factors Associated With Opioid Agonist Treatment Engagement and Harm Reduction Service Use: Findings From the New South Wales Opioid Dependence Survey. [PDF]

Drug Alcohol Rev
Santo T, Bharat C, Rodgers C, Harrod M, Taylor S, Zahra E, Sutherland R, Peacock A, Grebely J, Hickman M, Farrell M, Degenhardt L.   +11 more
europepmc   +1 more source

Erythropoietin modulates hepatic inflammation, glucose homeostasis, and soluble epoxide hydrolase and epoxides in high‐fat diet‐induced obese mice

FEBS Open Bio, EarlyView.
Erythropoietin administration suppresses hepatic soluble epoxide hydrolase (sEH) expression, leading to increased CYP‐derived epoxides. This is associated with a shift in hepatic macrophage polarization characterized by reduced M1 markers and increased M2 markers, along with reduced hepatic inflammation, suppressed hepatic lipogenesis, and attenuated ...
Takeshi Goda, Satoru Sugimoto, Chiharu Cho, Madoka Konishi, Nozomi Inoue, Satoshi Miyagaki, Yasuhiro Kawabe, Takuro Okamura, Masahide Hamaguchi, Hisakazu Nakajima, Michiaki Fukui, Masakazu Shinohara, Tomoko Iehara   +12 more
wiley   +1 more source

Understanding the role of street medicine in harm reduction: a case study of Street Medicine St. Louis. [PDF]

Harm Reduct J
Gzesh A, Truel JS, Adams DR, Zabotka L, Malone S, Nolan NS.   +5 more
europepmc   +1 more source

Message Valence, Industry Influence, and Stakeholder Narratives in Global Conversations on Tobacco Harm Reduction: Content Analysis. [PDF]

J Med Internet Res
Jun J, Zain A, Kim M, Thrasher J.
europepmc   +1 more source

Exploring disparities: a regional analysis of harm reduction supply distribution and opioid-related deaths across Ontario's Public Health Units. [PDF]

Harm Reduct J
Ledlie S, Scarfone K, Shearer D, Zurba N, Miskovic M, Munro C, Besharah J, Pinkerton S, Watts T, Gomes T.   +9 more
europepmc   +1 more source

Colonial harm in new packaging: Indigenous critiques of the tobacco industry's 'harm reduction' rhetoric. [PDF]

Health Promot Int
Maddox R, Heris C, Waa A, Teddy L, Upton P, Henderson PN, Kornacki C, Rodriguez J, Lee J, Tautolo ES, Martinez SA, Bradbrook SK, Kennedy M.   +12 more
europepmc   +1 more source

The role of stigma in impeding implementation of harm reduction services in San Francisco. [PDF]

SSM Qual Res Health
Akiba CF, Megerian CE, Chung EO, Morris T, Wenger LD, Suen LW, Lambdin BH, Kral AH.   +7 more
europepmc   +1 more source